Week In Review: Mevion Medical Of Boston Closes $150 Million Financing From China Investors

CStone Pharma of Suzhou has begun pivotal Phase II studies of its lead drug, a PD-L1 antibody, in two rare forms of lymphoma: natural killer cell/T-cell lymphoma and classical Hodgkin's lymphoma (see story). The two trials will test for efficacy and safety. According to CStone, CS1001 is China's first fully human, full-length, IgG4 based anti-PD-L1 monoclonal antibody, an IO drug that was independently developed by CStone. The first patients have been dosed the two trials.  

Everest Medicines, a US-China startup that in-licenses drugs for China's market, filed an IND to start a Phase III clinical trial of eravacycline in complicated intra-abdominal infections (cIAI) (see story). In February, Everest acquired greater China rights to eravacycline in a $43.5 million deal ($7 million upfront) from Tetraphase Pharma (Nasdaq: TTPH) of the US. Founded in 2017, Everest began operations with a $50 million investment from C-Bridge Capital, the first tranche of an initial round expected to raise $130 million.  

1 2 3
View single page >> |

Disclosure: None

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.